Background: The combination of tenofovir and efavirenz with either lamivudine or emtricitabine (TELE) has proved to be highly effective in clinical trials for first-line treatment of HIV-1 infection. However, limited data are available on its efficacy in routine clinical practice.
Methods: A multicentre cohort study was performed in therapy-naive patients initiating ART with TELE before July 2009. Efficacy was studied using ITT (missing or switch = failure) and on-treatment (OT) analyses. Genotypic susceptibility scores (GSSs) were determined using the Stanford HIVdb algorithm.
Results: Efficacy analysis of 1608 patients showed virological suppression to
Conclusions: In clinical practice, treatment failure on TELE regimens is relatively frequent due to toxicity. Virological failure is rare and more often observed with lamivudine than with emtricitabine. Following virological failure on TELE, PI-based second-line therapy was often successful despite GSS
- first-line antiretroviral therapy
- SINGLE-TABLET REGIMEN
- EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
- REVERSE-TRANSCRIPTASE INHIBITORS
- VIROLOGICAL FAILURE
- HIV-1 INFECTION
- RESISTANCE PROFILES
- HAART COMBINATIONS